echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sanofi Metadragon receives new indication in China for the treatment of sinus rhythm with a history of atrial fibrillation

    Sanofi Metadragon receives new indication in China for the treatment of sinus rhythm with a history of atrial fibrillation

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 22, Sanofi announced that the National Medical Products Administration (NMPA) of China has formally approved Maidarone (dronedarone hydrochloride tablets) for paroxysmal or persistent atrial fibrillation (abbreviated as " Atrial fibrillation") patients with a history of sinus rhythm, reduce the risk of hospitalization due to atrial fibrillation


    Atrial fibrillation refers to the loss of the normal rhythm of the atrial beating, which usually manifests as an irregular and rapid heart rate.


    As a new type of antiarrhythmic drug, Maidarone is more effective in maintaining sinus rhythm and reducing the recurrence of atrial fibrillation.


    Studies have shown that Maidarone is more effective in maintaining sinus rhythm and reducing the recurrence of atrial fibrillation


    Reference materials:

    [1] Just now | Sanofi's innovative drug for treatment of atrial fibrillation was approved in China.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.